Citalopram to treat depression in pediatric oncology

Margaret DeJong, Eric Fombonne

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.

Original languageEnglish (US)
Pages (from-to)371-377
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume17
Issue number3
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Citalopram
Fluoxetine
Pediatrics
Antidepressive Agents
Proxy
Drug Interactions
Half-Life
Serotonin
Age Groups
Safety
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Citalopram to treat depression in pediatric oncology. / DeJong, Margaret; Fombonne, Eric.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 17, No. 3, 06.2007, p. 371-377.

Research output: Contribution to journalArticle

@article{a720032c116e4a30ba2e42c09e9c9bdb,
title = "Citalopram to treat depression in pediatric oncology",
abstract = "We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.",
author = "Margaret DeJong and Eric Fombonne",
year = "2007",
month = "6",
doi = "10.1089/cap.2006.0076",
language = "English (US)",
volume = "17",
pages = "371--377",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Citalopram to treat depression in pediatric oncology

AU - DeJong, Margaret

AU - Fombonne, Eric

PY - 2007/6

Y1 - 2007/6

N2 - We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.

AB - We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.

UR - http://www.scopus.com/inward/record.url?scp=34447506372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447506372&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.0076

DO - 10.1089/cap.2006.0076

M3 - Article

C2 - 17630871

AN - SCOPUS:34447506372

VL - 17

SP - 371

EP - 377

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 3

ER -